All medicinal cannabis products supplied to Australian patients must meet quality standards
Published
Related content
-
TGA to expand quality audits for medicinal cannabis
Information for cannabis manufacturers regarding TGO 93 -
Search warrant executed on Sydney residence in relation to substandard compounded semaglutide
TGA officers executed a search warrant on a Sydney residence linked to an individual suspected of being involved in the manufacture and sale of compounded semaglutide. -
Trava Health Pty Ltd fined for alleged unlawful advertising of medicinal cannabis
The TGA has issued five infringement notices totalling $82,500 were issued to the company, and 3 notices totalling $9,900 were issued to an individual.